肠癌的简单查诊新方法

From: Employee Communications
Sent: Thu 3/17/2011 11:31 AM

The following is excerpted from a news release issued to the media 

ColoVantage(tm) colorectal cancer blood test

March 17, 2011 (Vol. 14, No. 36) -  ColoVantage test has been approved by New York State's Department of Health for testing on samples of patients in the state. It is believed to be the first molecular colorectal cancer detection method that employs a venal blood specimen to be approved by the state. 
 
 

Men and women at average risk for colorectal cancer should be screened beginning at age 50, according to the American Cancer Society, but only about half of this population nationally is up-to-date on screening. Some patients regard recommended tests, such as colonoscopy, flexible sigmoidoscopy and fecal occult blood tests (FOBTs), as invasive or unpleasant, and refuse or delay testing.

ColoVantage is designed to aid in the detection of colorectal cancer in patients who resist testing by guideline-recommended screening methods. Unlike other colorectal cancer tests, ColoVantage does not require dietary restrictions or special preparations and testing can be added to routine blood work. As with any noncolonoscopy test, a positive test result should be followed up by colonoscopy.

The test detects methylated DNA of the Septin9 gene from a specimen of blood taken from a patient's arm. The Septin9 biomarker has shown consistently high performance in colorectal cancer detection in several case-control studies. 

所有跟帖： 

• Intriguing. -恶俗老狼- ♂ (0 bytes) () 03/18/2011 postreply 10:05:34